Sandoz Opens Two European Sites, In Biosimilars And Antibiotics
Announcement Comes As Company Raises €2.0bn In Debt Following Spin
Executive Summary
Newly separated Sandoz has provided a trio of updates, foremost for its manufacturing and research ambitions for both biosimilars and antibiotics.
You may also be interested in...
Sandoz Sets Out Solid Growth In First Standalone Results
Reporting its first results as a standalone company, Sandoz has delivered double-digit growth in biosimilars for the first nine months of 2023, helping to lift the overall business as generics also enjoyed a more modest increase.
Sandoz Unveils $400m+ Investment In Slovenian Biosimilars Plant
Spurred on by “increasing global demand for biosimilar medicines,” Sandoz has revealed plans to invest at least $400m in building a new biologics production plant in Slovenia.
What’s Next? Five Things To Look Out For In December
Generics Bulletin previews the most noteworthy and anticipated events for December 2023.